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Aims Contemporary adjuvant treatment for early breast cancer is associated with improved survival but at the cost of in-
creased risk of cardiotoxicity and cardiac dysfunction. We tested the hypothesis that concomitant therapy with the
angiotensin receptor blocker candesartan or the b-blocker metoprolol will alleviate the decline in left ventricular ejec-
tion fraction (LVEF) associated with adjuvant, anthracycline-containing regimens with or without trastuzumab and
radiation.
Methods
and results
In a 2 × 2 factorial, randomized, placebo-controlled, double-blind trial, we assigned 130 adult women with early breast
cancer and no serious co-morbidity to the angiotensin receptor blocker candesartan cilexetil, the b-blocker metopro-
lol succinate, or matching placebos in parallel with adjuvant anticancer therapy. The primary outcome measure was
change in LVEF by cardiac magnetic resonance imaging. A priori, a change of 5 percentage points was considered clinically
important. There was no interaction between candesartan and metoprolol treatments (P ¼ 0.530). The overall decline
in LVEF was 2.6 (95% CI 1.5, 3.8) percentage points in the placebo group and 0.8 (95% CI 20.4, 1.9) in the candesartan
group in the intention-to-treat analysis (P-value for between-group difference: 0.026). No effect of metoprolol on the
overall decline in LVEF was observed.
*Corresponding author. Tel: +47 40107050, Fax: +47 67968860, Email: torbjorn.omland@medisin.uio.no
† The first two authors contributed equally to the study.
The work was performed at Akershus University Hospital.
& The Author 2016. Published by Oxford University Press on behalf of the European Society of Cardiology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/),
which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact
journals.permissions@oup.com
European Heart Journal (2016) 37, 1671–1680
doi:10.1093/eurheartj/ehw022
Conclusion In patients treated for early breast cancer with adjuvant anthracycline-containing regimens with or without trastuzumab
and radiation, concomitant treatment with candesartan provides protection against early decline in global left ventricu-
lar function.
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Introduction
Progress in detection and treatment of breast cancer during the past
two decades has led to substantial improvement in life expectancy
but at the cost of increased risk of unintended side effects of cancer
therapy.1 Adjuvant breast cancer treatment may encompass
anthracycline-containing chemotherapy and in patients with more
aggressive human epidermal growth factor receptor-2 (HER-2)-
positive cancers, the use of higher doses of anthracyclines followed
by taxanes and the anti-HER-2 agent trastuzumab. Both anthracy-
clines and trastuzumab have been associated with cardiotoxicity
and increased risk of developing asymptomatic and symptomatic
cardiac dysfunction.2 – 7 Given the increasing number of long-term
survivors after breast cancer treatment, cardiotoxicity has been re-
cognized as a major concern in oncology.1
Neuroendocrine blockade, including treatment with angiotensin-
converting enzyme inhibitors, angiotensin receptor blockers, and
b-blockers, has proved effective in reducing mortality and morbidity
in all stages of heart failure, and to prevent the transition from
asymptomatic to symptomatic left ventricular dysfunction.8 – 10 Ex-
perimental studies in animals11 as well as observational studies12
and small-scale, randomized, open-label,13,14 single-blind,15,16 or
double-blind,17 clinical trials in heterogeneous patient populations
with different cancer types and treatment regimens have suggested
a potential benefit from early initiation of angiotensin-converting
enzyme inhibitors and b-blockers in preventing anthracycline-
induced left ventricular dysfunction.12 – 18 However, a very recent
meta-analysis identified only 79 breast cancer patients who had
previously been included in randomized studies of b-blockers and
47 patients who had been included in randomized studies of
angiotensin-converting enzyme inhibitors or receptor blockers,18
and currently no data are available from randomized, placebo-
controlled, double-blind trials in breast cancer patients assessed
with cardiac magnetic resonance imaging (MRI) and highly sensitive
biochemical markers of cardiac injury. We therefore conducted a
randomized, 2 × 2 factorial, placebo-controlled, double-blind clin-
ical trial to test the hypotheses that concomitant therapy with the
angiotensin receptor blocker candesartan or the b-blocker meto-
prolol will attenuate the decline in left ventricular ejection fraction
(LVEF) associated with adjuvant, anthracycline-containing regimens
with or without trastuzumab and radiation for early breast cancer.
Methods
Study design and participants
PRevention of cArdiac Dysfunction during Adjuvant breast cancer ther-
apy (PRADA) was a 2 × 2 factorial, randomized, placebo-controlled,
double-blind clinical trial conducted at Akershus University Hospital,
Norway. The study complied with the Declaration of Helsinki. The
study protocol was approved by the Regional Ethics Committee of
South-Eastern Norway (2010/2890), and the trial was registered in
the ClinicalTrials.gov registry (NCT01434134) prior to study initiation.
All participants provided written, informed consent.
The rationale for and design of the study have been described in detail
previously.19 In brief, women who after breast cancer surgery in the per-
iod between September 2011 and September 2014 were scheduled to
initiate adjuvant chemotherapy with 5-fluorouracil, epirubicin, and
cyclophosphamide (FEC) and had no serious concomitant illness, prior
cardiovascular disease, and indication or contraindications for the study
drugs were eligible for inclusion. Detailed study inclusion and exclusion
criteria are listed in Supplementary material online, Table S1.
Randomization and masking
Participants were randomly assigned on a 1:1:1:1 basis to receive one of
the following treatment combinations: candesartan cilexetil 32 mg q.d.
and metoprolol succinate 100 mg q.d.; candesartan cilexetil 32 mg q.d.
and placebo q.d.; metoprolol succinate 100 mg q.d. and placebo q.d.; or
placebo and placebo q.d. Details on patient inclusion and randomization
are described in the Supplementary material online. Figure 1 summarizes
patient screening and randomization. A similar figure for the per-protocol
cohort is provided in the Supplementary material online, Figure S1.
Procedures
Patients were examined serially with cardiac MRI, blood samples, phys-
ical examinations, and electrocardiograms at the following time points
during the trial: at baseline, after completion of the first cycle of anthra-
cycline therapy, after completion of the final cycle of anthracycline ther-
apy, and for those concerned, at completion of trastuzumab or radiation
therapy (Supplementary material online, Figure S2). Echocardiography
was performed at the same time points, except for after completion
of the first cycle of anthracyclines. The duration of adjuvant therapy
ranged from 10 to 61 weeks depending on the anticancer regimens
(Supplementary material online, Figure S2).
Initiation of intervention commenced after baseline examination and
prior to initiation of chemotherapy. Dose titration is described in detail
in the Supplementary material online. Starting dose for candesartan ci-
lexetil was 8 mg and for metoprolol succinate 50 mg, target dose 32 and
100 mg, respectively. Compliance was registered by counting residual
tablets on every second visit during FEC treatment and every third visit
during trastuzumab treatment. In addition, the patients were given a
diary to register intake of tablets.
All cardiac MRI examinations were performed on a 1.5-T MRI scanner
(Achieva; Philips Medical Systems, Best, The Netherlands), using a
five-element phased-array cardiac coil. Breath-hold, steady-state-free-
precession sequences in contiguous, 8 mm thick short-axis images
covering the entire ventricles were used to quantify ejection fraction.
All image analyses were performed according to Society for Cardiovas-
cular Magnetic Resonance guidelines20 by a single, board-certified radi-
ologist (S.L.H.) blinded for treatment allocation and study order.
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Figure 1 Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): screening and randomization. *Excluded from all
analysis. The intention-to-treat population included all patients who had a valid measurement for the primary outcome, received chemotherapy,
and had no pre-randomization cardiac complications. HER, human epidermal growth factor receptor; MRI, magnetic resonance imaging.
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Transthoracic echocardiography was performed by using a Vivid E9 (GE
Vingmed, Horten, Norway). Images were digitally stored for offline ana-
lysis on custom software (EchoPAC, GE Vingmed, Horten, Norway).
Left ventricular, two-dimensional peak systolic global longitudinal strain
was analysed by an offline semi-automated speckle tracking imaging
technique from the three standard apical views. Diastolic function was
assessed by the ratio between peak early (E) transmitral velocity by
pulsed Doppler and peak early tissue Doppler (E′) by averaging septal
and lateral E′ at the base of septal and mitral leaflet, respectively. Ana-
lyses were performed by a board-certified physician (G.G.), who was
blinded to treatment assignment and study order. Detailed descriptions
of the cardiac MRI and echocardiographic analyses are provided in the
Supplementary material online.
Cardiac troponin I in serum was measured by using an assay from
Abbott Diagnostics: ARCHITECT STAT High Sensitive Troponin, as de-
scribed previously.21 The level of detection for this assay has been re-
ported to be 1.2 ng/L (range 0–50 000 ng/L) and the level of blank
0.8 ng/L.22 Samples with a level below or equal to the level of blank (i.e.
0.8 ng/L) were assigned a value of 0.8, whereas levels below or equal to
the level of detection (i.e. 1.2 ng/L) and greater than the level of blank,
were assigned a value of 1.2 ng/L. The coefficient of variation of 10%
has been observed at a concentration of 3.0 ng/L. B-type natriuretic pep-
tide (BNP) in plasma was measured by a chemiluminescent microparticle
immunoassay (BNP, Abbott Diagnostics; ARCHITECT). The level of de-
tection is 10 pg/mL. Samples with a level,10 pg/mL were assigned a con-
centration of 5 pg/mL.
Outcome measures
The primary outcome measure of the trial was change in LVEF from
baseline to the completion of adjuvant anticancer therapy, as deter-
mined by cardiac MRI. Secondary outcome measures included change
in right ventricular ejection fraction, as determined by MRI, left ventricu-
lar peak systolic global longitudinal strain by two-dimensional speckle
tracking imaging, diastolic function (E/E′), and concentrations of cardiac
troponin I by a high-sensitivity assay. Other biomarker and echocardio-
graphic indices of diastolic function were considered tertiary outcome
measures. A Data Safety and Monitoring Board consisting of a cardiolo-
gist, an oncologist, and a statistician was constituted prior to the
initiation of the study and monitored adverse events.
Statistical analysis
With a of 0.05, and power (1 2 b) of 0.95, 26 patients treated with can-
desartan and 26 patients treated with metoprolol were required to de-
tect an absolute between-group difference in change in LVEF of 5+5%
(SD) percentage points. With a dropout rate of 17%, the adjusted tar-
geted inclusion was estimated to be a minimum of 120 patients. Out of
the 120 patients included in the analysis, 28 received candesartan–
metoprolol, 32 candesartan–placebo, 30 metoprolol–placebo, and 30
placebo–placebo (Figure 1).
The primary efficacy analysis was performed on an intention-to-treat
sample consisting of all validly randomized patients with at least baseline
MRI, and a per-protocol sample. All secondary efficacy analyses were
also performed on both the intention-to-treat sample and a per-
protocol sample. The per-protocol analysis excluded patients who did
not have baseline and end-of-study MRI measurements, were not com-
pliant to intervention or discontinued their study medication, withdrew
consent, or did not complete adjuvant therapy.
For each continuous efficacy endpoint, we fitted a linear mixed model
to all available measurements from three time points: (i) baseline, (ii)
after completion of the first cycle of anthracycline therapy, and (iii)
end-of-study (either after completion of the final cycle of anthracycline
therapy or the completion of trastuzumab or radiation therapy). All
models included fixed effects for time, candesartan treatment,
metoprolol treatment, candesartan treatment × time interaction,
metoprolol treatment × time interaction, age, and left-sided radiation,
and a random intercept. To investigate possible interactions between
the two treatments, we fitted additional models that included a
candesartan × metoprolol interaction term, and applied a likelihood ra-
tio test to the models with and without the treatment interaction term.
No statistically significant treatment interactions were observed. Based
on the fitted models without the treatment interaction term, we esti-
mated baseline, end-of-study (i.e. the final visit), and change from base-
line to end-of-study mean values (with 95% CI) for patients in four
groups: (i) treated with candesartan, (ii) not treated with candesartan,
(iii) treated with metoprolol, and (iv) not treated with metoprolol.
The treatment effects were estimated as the between-group difference
in change from baseline to end-of-study for the comparisons of cande-
sartan vs. no candesartan and metoprolol vs. no metoprolol. Troponin I
values were log transformed before inclusion in the linear mixed mod-
els. All terms in the linear mixed models were pre-specified in the stat-
istical analysis plan.
A P-value of ,0.05 was considered statistically significant. The re-
ported P-values are two-sided and not adjusted for multiple comparisons.
The statistical analyses were carried out with Stata 14.0 (StataCorp LP).
Results
Between September 2011 and September 2014, 120 patients with
early breast cancer having surgery at Department of Surgery at
Akershus University Hospital and scheduled for adjuvant therapy
with the anthracycline epirubicin were enrolled in the trial and val-
idly randomized to one of the four treatment groups (Figure 1). The
four groups were well-balanced concerning patient characteristics
at baseline and planned adjuvant anticancer therapy (Table 1). De-
tails of the cancer characteristics are given in the Supplementary ma-
terial online, Table S2. Adjuvant therapy was administered according
to the recommendations of the Norwegian Breast Cancer Group.
All patients received FEC, and if indicated taxanes (n ¼ 100;
79.4%), trastuzumab (n ¼ 28; 22.2%) and radiotherapy (n ¼ 82;
65.1%). No patient developed symptomatic heart failure during
the study period.
There was no statistical interaction between candesartan and
metoprolol treatment on the primary endpoint (P ¼ 0.53) or on
any of the secondary endpoints. Accordingly, the patients in the
two groups receiving candesartan were compared with patients re-
ceiving placebo–placebo or metoprolol–placebo (Table 2). The
overall decline in the primary outcome measure from baseline to
the end-of-study was 2.6 (95% CI 1.5, 3.8) percentage points in
the placebo group and 0.8 (95% CI 20.4, 1.9) percentage points
in the candesartan group in the intention-to-treat analysis (P-value
for between-group difference in linear mixed model analysis:
0.026). Corresponding values in the per-protocol analysis were
2.6 (95% CI 1.4, 3.8) percentage points in the placebo group and
0.6 (95% CI 20.6, 1.8) percentage points in the candesartan group
(P ¼ 0.021 in mixed linear model). Notably, the effect of candesar-
tan on change in LVEF was not influenced by adjustment for change
in systolic blood pressure. The effect of candesartan on LVEF was
consistent across predefined subgroups with no significant inter-
action observed when patients were stratified according to age,
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current smoking, history of hypertension, body mass index, radi-
ation, or trastuzumab (Figure 2A). No significant effect of candesar-
tan was observed for right ventricular ejection fraction, left
ventricular global longitudinal strain, E/E′, cardiac troponin I (Ta-
ble 2), or BNP (Supplementary material online, Tables S3 and S4).
The effect of candesartan on diastolic function indices is summar-
ized in Supplementary material online, Table S3.
In the two groups that were assigned to metoprolol, the mean
LVEF reduction was 1.6 (95% CI 0.4, 2.8) percentage points from
baseline to the end-of-study, whereas in the two groups assigned
to placebo the corresponding decrease was 1.8 (95% CI 0.7, 3.0).
This between-group difference was not statistically significant
(P ¼ 0.77) (Figure 2B). There were small but statistically significant in-
creases in E/E′ and BNP levels in the group that received metoprolol
compared with the group that did not receive metoprolol. Otherwise,
no effect of metoprolol was observed for the secondary outcome
measures listed in Table 2 or the diastolic function indices listed in Sup-
plementary material online, Table S3. The effect of metoprolol on
heart rate is shown in Supplementary material online, Figure S3.
When considering the four randomization groups separately and
using the placebo–placebo group as the reference [22.8 (95% CI
24.3, 21.3)], the reduction in LVEF was significantly less in the can-
desartan–placebo group than in the placebo–placebo group [20.9
(95% CI 22.3, 0.4); P ¼ 0.025] but not significantly less in the can-
desartan–metoprolol group than in the placebo–placebo group
[20.6 (95% CI 22.1, 0.8); P ¼ 0.075]. No significant difference
was observed between the placebo–placebo group and the meto-
prolol–placebo group [22.5 (95% CI 23.9, 21.1); P ¼ 0.71]
(Supplementary material online, Table S5).
Compliance, side effects, and serious
adverse events
Compliance with study drugs was generally excellent. Two, one,
three, and three patients did not adhere to the assigned candesartan,
candesartan–placebo, metoprolol, and metoprolol–placebo, re-
spectively, at completion of adjuvant therapy. The mean daily study
drug dose at completion of adjuvant therapy was 23+ 11 mg for
candesartan, 26+ 9 mg for candesartan–placebo, 68+ 34 mg for
metoprolol, and 78+ 32 mg for metoprolol–placebo. There
were no unexpected serious adverse events, the intervention was
well tolerated, and no patient in the intention-to-treat analysis
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Table 1 Baseline characteristics of the study population
Candesartan–metoprolol Candesartan–placebo Placebo–metoprolol Placebo–placebo
n 30 32 32 32
Age at recruitment (years) 50.0+8.9 51.7+10.7 50.5+9.1 50.8+9.2
Height (cm) 166.8+6.6 165.5+6.8 167.1+6.1 168.0+5.5
Weight (kg) 70.3+11.3 71.4+14.3 77.7+18.1 72.3+13.7
Systolic blood pressure (mmHg) 124.7+12.8 131.9+14.1* 134.4+13.1** 130.3+12.9
Diastolic blood pressure (mmHg) 78.2+11.5 80.5+8.5 80.5+11.3 80.2+9.9
Heart rate (b.p.m.) 70.8+11.4 71.7+6.7 73.3+10.1 68.3+11.6
Body mass index (kg/m2) 25.3+3.6 25.9+4.3 27.8+6.3 25.6+4.5
Current smokers 6/30 (20.0%) 7/32 (21.9%) 5/32 (15.6%) 7/32 (21.9%)
Hypertension 1/30 (3.3%) 5/32 (15.6%) 2/32 (6.3%) 0/32 (0%)
Diabetes 0/30 (0%) 1/32 (3.1%) 1/32 (3.1%) 0/32 (0%)
Serum troponin I ≥1.2 ng/L 7/30 (23.3%) 12/32 (37.5%) 9/32 (28.1%) 13/32 (40.6%)
Serum creatinine (mg/dL) 0.75+0.11 0.73+0.10 0.79+0.10 0.74+0.10
Blood haemoglobin (g/dL) 13.2+0.9 13.3+1.0 13.4+0.7 13.2+0.8
Baseline MRI (n) 28 32 30 30
Left ventricular ejection fraction (%) 62.2+4.4 62.3+5.3 63.5+5.0 63.6+4.1
Right ventricular ejection fraction (%) 60.6+5.2 60.0+5.2 62.0+4.8 61.2+4.8
Baseline peak systolic global longitudinal
strain (n)
24 21 23 25
Peak systolic global longitudinal strain 221.7+1.6 221.2+1.7 221.7+2.2 221.6+1.5
Baseline E/E′ (n) 29 30 31 32
E/E′ 7.3+2.1 7.5+1.9 6.7+2.1 7.5+1.9
Additional therapy after FEC
Trastuzumab 7/30 (23.3%) 7/32 (21.9%) 7/32 (21.9%) 7/32 (21.9%)
Radiation 18/30 (60.0%) 19/32 (59.4%) 22/32 (68.8%) 23/32 (71.9%)
Taxanes 25/30 (83.3%) 25/32 (78.1%) 26/32 (81.3%) 24/32 (75%)
Data are expressed as mean+ SD or numbers (per cent).
MRI, magnetic resonance imaging; FEC, 5-fluorouracil, epirubicin, and cyclophosphamide; E/E′ , diastolic function.
*P, 0.05 for the comparison with candesartan–metoprolol; **P, 0.01 for the comparison with candesartan–metoprolol; there were no significant differences between
the four study groups, except as noted.
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was withdrawn because of adverse events. Details concerning the
serious adverse events are summarized in Supplementary material
online, Table S6.
Discussion
This randomized, placebo-controlled, double-blind clinical trial de-
monstrates that in patients with early breast cancer, contemporary
anthracycline-containing adjuvant regimens are associated with a
numerically modest absolute reduction in left ventricular systolic
function and that concomitant administration of the angiotensin re-
ceptor blocker candesartan significantly alleviates the decline in
LVEF that occurs during adjuvant therapy. Importantly, the effect
seemed independent of a direct haemodynamic effect of candesar-
tan as adjustment for change in systolic blood pressure did not im-
pact on the results. No significant beneficial effect of candesartan
was observed for the secondary endpoints right ventricular ejection
fraction, left ventricular global longitudinal strain, and E/E′, probably
reflecting the higher methodological variability of these
measurements compared with MRI assessment of LVEF.23 Cande-
sartan was also ineffective in reducing the increase in circulating car-
diac troponin I associated with anthracycline-containing adjuvant
therapy, suggesting that angiotensin receptor blockade may not
interfere with the direct cardiotoxic effect of anthracyclines, but ra-
ther plays a role in the myocardial remodelling process that occurs
after cardiac injury.24
In contrast to the attenuation of the reduction in left ventricular
function observed for candesartan, no short-term beneficial effect
was observed for the b-blocker metoprolol. This is in contrast to
findings in some prior, small-scale, randomized studies.14,15,17 Po-
tential reasons for this apparent discrepancy include that patients
in prior studies may have received higher doses of anthracyclines
and had a higher prevalence of cardiovascular co-morbidities, which
could contribute to a favourable effect of b-blockade. Moreover,
given that the reduction in LVEF in the placebo–placebo group in
our study was less than originally anticipated, the power of the study
to detect between-group differences was reduced. Accordingly, the
apparent lack of effect of metoprolol on LVEF may also be due to
inadequate statistical power and does not rule out a beneficial effect
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Table 2 Primary and secondary endpoints, estimated values from linear mixed models (intention-to-treat analysis)
n Baseline EOS Change from
baseline to EOS
Between-group difference in
change from baseline to EOS
P-value
LVEF
No candesartan 60 63.2 (62.0, 64.4) 60.6 (59.4, 61.8) 22.6 (23.8, 21.5) 1.9 (0.2, 3.5)a 0.026
Candesartan 60 62.1 (61.0, 63.3) 61.4 (60.2, 62.6) 20.8 (21.9, 0.4)
No metoprolol 62 62.8 (61.6, 64.0) 61.0 (59.8, 62.2) 21.8 (23.0, 20.7) 0.2 (21.4, 1.9) 0.772
Metoprolol 58 62.5 (61.3, 63.7) 61.0 (59.8, 62.2) 21.6 (22.8, 20.4)
RVEF
No candesartan 60 61.3 (60.0, 62.5) 58.9 (57.6, 60.1) 22.4 (23.7, 21.1) 0.8 (21.0, 2.6) 0.370
Candesartan 60 60.2 (59.0, 61.4) 58.7 (57.4, 59.9) 21.6 (22.8, 20.3)
No metoprolol 62 60.4 (59.2, 61.6) 58.0 (56.8, 59.3) 22.4 (23.7, 21.1) 0.8 (21.0, 2.6) 0.377
Metoprolol 58 61.1 (59.8, 62.3) 59.5 (58.3, 60.8) 21.6 (22.9, 20.3)
LV GLS
No candesartan 48 221.6 (222.1, 221.1) 221.0 (221.5, 220.5) 0.6 (0.1, 1.1) 20.7 (21.4, 0.1) 0.076
Candesartan 45 221.3 (221.8, 220.7) 221.3 (221.9, 220.8) 20.1 (20.6, 0.5)
No metoprolol 46 221.4 (221.9, 220.8) 221.0 (221.6, 220.5) 0.3 (20.2, 0.8) 20.1 (20.8, 0.7) 0.824
Metoprolol 47 221.5 (222.0, 221.0) 221.3 (221.8, 220.7) 0.2 (20.3, 0.7)
E/E′
No candesartan 63 7.1 (6.6, 7.6) 7.2 (6.7, 7.7) 0.1 (20.4, 0.5) 0.1 (20.5, 0.8) 0.688
Candesartan 59 7.4 (6.9, 7.9) 7.6 (7.1, 8.1) 0.2 (20.2, 0.7)
No metoprolol 62 7.4 (7.0, 7.9) 7.2 (6.7, 7.7) 20.3 (20.7, 0.2) 0.8 (0.2, 1.5) 0.009
Metoprolol 60 7.1 (6.6, 7.5) 7.6 (7.1, 8.1) 0.6 (0.1, 1.0)
Troponin Ib
No candesartan 64 1.1 (0.9, 1.2) 2.7 (2.3, 3.1) 2.5 (2.0, 3.1) 1.1 (0.8, 1.4) 0.666
Candesartan 62 1.0 (0.8, 1.1) 2.5 (2.2, 2.9) 2.6 (2.2, 3.2)
No metoprolol 64 1.1 (0.9, 1.3) 2.8 (2.4, 3.3) 2.6 (2.1, 3.2) 1.0 (0.7, 1.3) 0.831
Metoprolol 62 0.9 (0.8, 1.1) 2.4 (2.0, 2.8) 2.5 (2.0, 3.1)
Data are expressed as mean (95% CI).
LVEF, left ventricular ejection fraction; RVEF, right ventricular ejection fraction; LV GLS, left ventricular peak systolic global longitudinal strain; EOS, end-of-study; E/E′ , diastolic
function.
aRounding effect.
bGeometric means.
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Figure 2 Effect of candesartan and metoprolol on left ventricular ejection fraction during adjuvant therapy for early breast cancer. Shown are
the changes in left ventricular ejection fraction expressed in percentage points with 95% confidence intervals. Concomitant therapy with cande-
sartan alleviated the decline in left ventricular ejection fraction observed in the placebo group. This effect was consistent across subgroups with no
formal interaction observed when patients were stratified according to age, current smoking, history of hypertension, body mass index, trastu-
zumab, or radiation (A). No effect of metoprolol on the mean left ventricular ejection fraction was observed (B). Median age at baseline was 49
years, and median body mass index at baseline was 25.6 kg/m2. EOS, end-of-study; LVEF, left ventricular ejection fraction by magnetic resonance
imaging; BMI, body mass index.
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of b-blockade. Finally, we cannot rule out the possibility that an al-
ternative b-blocker or a higher dose would have proved effective.
Although some studies have indicated that echocardiographic in-
dices of diastolic function may detect subclinical changes in cardiac
function during cancer treatment, their predictive value remains un-
proven.23,25 Moreover, in the oncological setting, changes in diastol-
ic indices such as the E/E′ ratio could be the result of changes in
loading conditions secondary to the nausea and vomiting commonly
associated with chemotherapy.25 We observed a small increase in
E/E′, an index closely associated with left ventricular filling, in the
metoprolol but not in the no-metoprolol group. This increase is
likely associated with a direct haemodynamic effect of b-blockade.26
Similarly, BNP concentrations increased in the metoprolol group
but remained unchanged in the candesartan group during adjuvant
chemotherapy. It is well documented that b-blockade, via its effects
on heart rate and stroke volume, causes increased release of natri-
uretic peptides.27 Accordingly, in the absence of development of
symptomatic ventricular dysfunction, it is not surprising that meto-
prolol is associated with an increase in BNP levels in the current
study. The lack of effect of candesartan on BNP can probably be
accounted for by its relatively high intra- and inter-individual vari-
ability28 and is in accordance with other recent studies examining
the effect of anthracycline therapy on BNP.29
The current results may have potential important implications. A
reduction in LVEF is commonly considered a late-occurring phe-
nomenon in the cardiotoxic process, manifesting itself first after
myocardial reserves are exhausted.1 This study, using the reference
method for assessment of left ventricular function, demonstrates
that low-to-moderate doses of anthracyclines with or without tras-
tuzumab or radiation are associated with a numerically modest, but
significant reduction in LVEF that was somewhat less than that we a
priori had defined as a clinically important difference. This observa-
tion is in accordance with another recent, smaller (n ¼ 58 with car-
diac MRI imaging) randomized, controlled, but non-blinded trial of
malignant haemopathies receiving anthracycline-based chemother-
apy that found an absolute reduction of LVEF of 3.0 percentage
points in the placebo group.14 Moreover, our findings are in accord-
ance with those of an observational study using cardiac MRI in a
more heterogeneous population of cancer patients (n ¼ 53) treated
with low-to-moderate dose anthracycline-based chemotherapy.2
Although the latter study included patients with prior coronary ar-
tery disease and a high proportion of patients had hypertension
(40%) and other cardiovascular risk factors, the absolute reduction
in LVEF was only moderately higher than in the current, all-female
previously healthy study population. Taken together, these studies
consistently show that contemporary doses of anthracycline-
containing chemotherapy regimens are associated with a modest,
but highly statistically significant reduction of LVEF, but that develop-
ment of severe ventricular dysfunction is a rare-occurring event in
the short term.
A crucial question, however, is whether these numerically mo-
dest early changes in LVEF and the prevention of early decline in
ventricular function may have any consequences for the long-term
risk of developing more severe asymptomatic or symptomatic ven-
tricular dysfunction. As imaging methods used in the past may have
lacked the precision to identify minor LVEF changes, the long-term
implications of reduction in LVEF following the exposure to
cardiotoxic agents are not yet fully known, but it is well documented
that the process of left ventricular dysfunction after other types of
myocardial injury is progressive and early intervention is crucial to
prevent deterioration in the long term. The notion of the import-
ance of early intervention is also supported by observational data,
suggesting that the duration from completion of high-dose anthracy-
cline therapy to initiation of angiotensin-converting enzyme inhib-
ition is a key determinant of the magnitude of the beneficial
effect.30 This was recently highlighted by Cardinale et al., who in a
prospective study of 2625 anthracycline-receiving patients reported
an association between end-of-chemotherapy LVEF and cardiotoxi-
city development.6 In our study, concomitant treatment with cande-
sartan prevented the early LVEF decline associated with adjuvant
therapy for breast cancer. Accordingly, it seems likely that this at-
tenuation of the early decline in ventricular function may have bene-
ficial long-term consequences concerning the risk of developing
asymptomatic or symptomatic ventricular dysfunction.
Strengths of the current study include the 2 × 2 factorial design,
permitting a head-to-head comparison of two different drugs, the
use of serial cardiac MRI investigations in a homogeneous cohort
of patients with breast cancer treated with contemporary adjuvant
therapy, including low-to-moderate doses of epirubicin. According-
ly, our results are generalizable to a large number of women with
early breast cancer. Using a method with low variability, the current
trial had a high likelihood to detect even modest differences be-
tween groups. Limitations of the current report include the lack
of follow-up information beyond the adjuvant therapy period, but
long-term follow-up of the participants with repeat cardiac MRI
investigations is planned. We excluded some patients at high cardio-
vascular risk, but many of these, including those with prior cardio-
vascular disease, had indications for treatment with b-blockers or
inhibitors of the renin–angiotensin system. The dose of metoprolol
attained was moderately high, but resulted in a significant reduction
in heart rate compared with the placebo group, suggesting good
compliance and adequate b-blockade. Although predefined sub-
group analyses showed a consistent effect across subgroups, includ-
ing those who received higher dose anthracyclines and trastuzumab,
the statistical power to conduct subgroup analyses in this study is
limited, and this observation must be verified in adequately powered
trials with long-term follow-up.
In conclusion, using cardiac MRI we found that adjuvant breast
cancer treatment is associated with a decline in LVEF that is alle-
viated by concomitant neurohormonal blockade with candesartan.
Long-term follow-up of these patients will document whether the
beneficial effect of candesartan is sustained and will translate into
reduced incidence of left ventricular dysfunction.
Supplementary material
Supplementary material is available at European Heart Journal online.
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Cerebral ‘metastasizing’ cardiac myxoma
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A 41-year-old female patient presented with dys-
pnoea and peripheral oedema non-responsive to
diuretic treatment. In the course of disease, the
patient suffered from new onset of dizziness. Cere-
bral magnetic resonance (MR) imaging demon-
strated diffusion restriction in the left frontal lobe
in keeping with acute embolic ischaemic events
(Panel A). Multiple fusiform aneurysms were
detected in MR angiography (Panel B). The gold
standard of conventional angiography produced
proof of findings predominantly in middle cerebral
artery territories (Panel C, arrow) and growth at
follow-up (Panel D).
Echocardiography for stroke work-up showed a
pedunculated left atrial mass originating from the
oval fossa with diastolic dislocation into the mitral
valve (diastolic gradient ¼ 6 mmHg, Panels E and F).
Coronary computed tomography (CT) angiog-
raphy ruled out concomitant coronary artery dis-
ease before surgery (Panel G). Surgical resection
was performed radically without complications.
An investigational 18F-fluoroethyl-tyrosine posi-
tron emission tomography (PET) of the brain
demonstrated increased tracer uptake with
tumor-to-background ratio (TBR) indicative of a
low-grade tumour (TBR ¼ 2.6, Panel H). Histopathology demonstrated aneurysmal dilatation of the sampled artery with intramural
and intraluminal infiltrates of spindled tumour cells in a myxoid matrix with sparse mitotic activity. Cytostatic treatment with carboplatin
and etoposide was initiated and resulted in a decreasing tracer uptake at follow-up (TBR ¼ 1.5, Panel I) and stable aneurysm sizes.
Left atrial myxoma comprises the majority of cardiac tumours and may lead to embolic ischaemic strokes. In rare cases, neurological
impairment may arise from metastatic spread and myxomatous aneurysm formation with or without haemorrhage. In such cases, active
surveillance is not an option. Chemotherapy may prevent patients from aneurysm growth but other therapeutic options are valid
including radiotherapy and surgery.
Supplementary material is available at European Heart Journal online.
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